Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Efficacy Trial of The Toolkit for Optimal Recovery After Concussion

NCT07923864 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07923864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
An Efficacy Trial of The Toolkit for Optimal Recovery After Concussion
Lead sponsor
Massachusetts General Hospital
Phase
Not applicable
Overall status
Not yet recruiting
Start date
June 30, 2027
Completion date
December 31, 2030
Enrollment
260 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anxiety, concussion (diagnosis), mild traumatic brain injury, post concussion symptoms

Arms

As registered; 2 arms.

  • Toolkit for Optimal Recovery after Concussion (TOR-C) ExperimentalToolkit for Optimal Recovery after Concussion (TOR-C)

    A 4-week mind-body program delivered via live video (Zoom) 1:1 with a clinician delivering mind-body and cognitive-behavioral skills.

  • Health Enhancement after Concussion (HE-C) Active comparatorHealth Enhancement after Concussion (HE-C)

    A 4-week program delivered via live video (Zoom) 1:1 with a clinician delivering psychoeducation and information about healthy living after a concussion

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Post-Concussion Symptom Scale (PCSS) Baseline (week 0), post-test (week 4), 6-month follow-up (week 28)

    Measures the severity of concussion symptoms (e.g., headache, fatigue, dizziness, difficulty concentrating). This is the study's primary outcome; efficacy is judged mainly on reducing these symptoms.

Lead sponsor's other trials

Massachusetts General Hospital, most recent start first.

Similar trials

Same condition (Post-Concussion Syndrome) and phase, most recent start first.